Status:
COMPLETED
LOQTEQ® Antibacterial Pre-Market Study
Lead Sponsor:
aap Implantate AG
Collaborating Sponsors:
German Federal Ministry of Education and Research
Conditions:
Fractures, Open
Fractures, Closed
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
aap001 is a randomized, controlled, subject-blinded, multi-center study to show the safety of the LOQTEQ® antibacterial silver-coated system is non-inferior in comparison with the uncoated LOQTEQ® sys...
Detailed Description
Antimicrobial coatings of implants are of interest to reduce infection rate in orthopaedic surgery. Demonstration of clinical effectiveness of such coated implants to obtain market approval is challen...
Eligibility Criteria
Inclusion
- Able and willing to provide voluntary written Informed Consent prior to any study related procedure.
- Subject aged 18 years and over.
- Subjects with fractures of the distal fibula.
Exclusion
- Subject unable to give written informed consent, is unlikely to cooperate or is legally incompetent.
- Subjects with consumptive / malignant primary disease and a life expectancy of less than 12 months.
- Subjects with a known allergy to silver or any components of the device.
- Subjects with an already implanted silver-coated device other than the investigational device.
- History of or ongoing chronic soft-tissue and/or bone and/or implant infection signs at the distal tibia and/or distal fibula (not related to current fracture).
- Subjects with a possible contraindication for the investigational and comparator devices
- infection or inflammation requiring treatment with antibiotics or with positive cultures (not related to current fracture);
- acute and chronic osteomyelitis at or close to the surgical field (not related to current fracture);
- high anesthesia risk subjects (ASA Physical Status Classification of 4 to 6);
- subjects with neurological disorders who cannot follow instructions given by their physician;
- subjects with past history of severe medical disorders of extremity which may impact study device efficacy and safety according to investigator\'s judgment;
- severe chronic or acute comorbidity according to investigator's judgement (such as arthritis or neurogenic disorders).
- Female subjects who are pregnant or lactating at Screening Visit.
- Females who are of childbearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of childbearing potential taking acceptable contraceptive precautions according to investigator's judgement can be included.
- Males with partners who are pregnant or lactating or of childbearing potential and are unwilling to use condoms for the duration of the study. Males who are unable or unwilling to use condoms can be included if partners of childbearing potential taking acceptable contraceptive precautions according to investigator's judgement.
- Participation in any other study involving an investigational drug or device currently or within the past 3 months.
- Subject has a significant history of drug/solvent abuse.
- Subject has a history of alcohol abuse or currently drinks more than 224 g alcohol for men and 112 g alcohol for women per week.
- Subjects with stage IV vascular disease, i.e. with presence of necrotic tissue at the distal tibia.
Key Trial Info
Start Date :
December 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2025
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT05260463
Start Date
December 9 2021
End Date
August 4 2025
Last Update
September 18 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinikum Regensburg
Regensburg, Bavaria, Germany, 93042
2
Unfallkrankenhaus Berlin
Berlin, Germany, 12683
3
Helios Klinikum Berlin-Buch GmbH
Berlin, Germany, 13125
4
Städtisches Klinikum Dresden
Dresden, Germany, 01067